Skip to main content
. 2024 Feb 4;21(4):674–680. doi: 10.7150/ijms.91804

Table 1.

Baseline characteristics of the patients in the derivation and validation cohorts

Characteristic Total (N=410) Derivation cohort (N=290) Validation cohort (N=120) P
Age (years) 34(28, 45) 34(28, 44) 34(27, 47) 0.569
Men, n (%) 133(32.44) 93(32.07) 40(33.33) 0.803
BMI (kg/m2) 22.50(20.50, 24.96) 22.42(20.70, 25.13) 22.50(20.30, 24.30) 0.552
Hypertension, n (%) 135(32.93) 98(33.79) 37(30.83) 0.562
UPE (g/d) 0.182
<1 261(63.66) 185(63.79) 76(63.33)
1-3.5 118(28.78) 79(27.24) 39(32.50)
≥3.5 31(7.56) 26(8.97) 5(4.17)
Hematuria (RBCs/ul) 54.00(20.00, 149.25) 54.00(18.00, 150.00) 61.00(22.25, 146.25) 0.341
Serum creatinine (μmol/L) 89.00(71.75, 125.00) 89.00(71.00, 125.00) 89.00(73.00, 121.00) 0.632
Serum cystatin C 1.00(0.82, 1.37) 0.97(0.82, 1.36) 1.02(0.84, 1.39) 0.504
Serum albumin (g/L) 36.40(32.70, 40.02) 36.75(32.78, 40.30) 35.60(32.60, 39.48) 0.272
Hs-CRP (mg/L) 0.78(0.32, 1.99) 0.80(0.31, 1.99) 0.66(0.33, 2.01) 0.936
eGFRcr-cys (mL/min/1.73m2) 80.44(50.48, 103.30) 81.27(50.30, 104.00) 78.60(54.69, 101.44) 0.552
Serum IgG (g/L) 11.80(9.55, 13.80) 11.90(9.77, 13.83) 11.60(9.35, 13.48) 0.307
Serum IgA (g/L) 3.16(2.51, 3.99) 3.15(2.49, 3.98) 3.18(2.60, 4.07) 0.744
Serum IgM (g/L) 1.08(0.79, 1.47) 1.08(0.80, 1.43) 1.04(0.76, 1.55) 0.938
Serum C3 (mg/L) 1030.00(916.75, 1170.00) 1040.00(920.00, 1170.00) 1005(895, 1178) 0.785
Serum C4 (mg/L) 246.00(201.00, 305.25) 247.50(203.00, 305.00) 243(198, 308) 0.809
Oxford MEST-C, n (%)
M1 385(93.90) 270(93.10) 115(95.8) 0.293
E1 81(19.80) 58(20.00) 23(19.2) 0.874
S1 196(47.80) 137(47.20) 59(49.2) 0.723
T1/2 124(30.20) 82(28.30) 42(35.0) 0.177
C1/2 221(53.90) 149(51.40) 72(60.0) 0.111

Results are presented as mean SD, median (interquartile range), or number (percentage).

Groups were compared by using Kruskal-Wallis or F test

BMI body mass index; UPE urinary protein excretion; eGFR estimated glomerular filtration rate; hs-CRP high-sensitivity C-reactive protein; MEST-C, M mesangial hypercellularity; E endocapillary hypercellularity; S segmental glomerulosclerosis; T interstitial fibrosis/tubular atrophy; C crescent formation.